NAIFF ALI: Open Payments
NPI 1992151401 · DEARBORN HEIGHTS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,856 in 126 payments from 30 companies in 2025. Trend: 2023 $2,860 · 2024 $2,224 · 2025 $2,856
Food & beverage: $2,856
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 23 | $920 |
| ABBVIE INC. | 17 | $336 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $256 |
| Novo Nordisk Inc | 13 | $237 |
| GlaxoSmithKline, LLC. | 7 | $178 |
| Axsome Therapeutics, Inc. | 8 | $140 |
| E.R. Squibb & Sons, L.L.C. | 5 | $81 |
| Merck Sharp & Dohme LLC | 3 | $71 |
| PFIZER INC. | 4 | $67 |
| Lundbeck LLC | 3 | $64 |
Products named: AIRSUPRA, VRAYLAR, CAPLYTA, Wegovy, REXULTI, TRELEGY ELLIPTA, AREXVY, Rybelsus.
Industry payments across MI — which companies pay providers there.
